Where Will the Next Generation of Senior Pharma Consultants Come From?

I find myself returning to this question often. I do not yet have a complete answer.

Much of what shaped my professional judgment early in my career came from work that was repetitive, detailed, and largely invisible from the outside. Routine validation activities. Long deviation reviews. Afternoons spent reading SOPs until they stopped feeling like documents and started feeling like systems. That work required patience, but it built something that is difficult to name precisely and easy to recognize: the ability to read complexity in regulated environments before it becomes a problem.

Today, much of that same work can be completed by AI in minutes.

When the Foundation Changes

For many years, life sciences consulting relied on gradual exposure to real processes as the primary way professionals developed judgment. Junior consultants learned how documentation reflects risk, how decisions move across functions, and how small details shape outcomes during inspections or remediation programs. This learning was slow, but it was also reliable in a way that mattered: it produced people who had seen enough to trust their own instincts.

A professional entering the industry today will not move through those same first five years. The work that once built this foundation has changed faster than our models for developing the people who depend on it, and that gap deserves more honest attention than it currently receives.

Technology Changes Work Faster Than It Changes Learning

Artificial intelligence is already reshaping how validation documentation is prepared, how deviations are analyzed, and how procedural information is interpreted across organizations. These are meaningful advances that allow teams to move faster and focus their effort where it matters most. But they also quietly remove some of the experiences through which consultants traditionally learned to recognize patterns, accumulate context, and develop the instinct that separates a good recommendation from a technically correct one.

The need for judgment has not diminished. If anything, as AI takes on more of the procedural layer, judgment becomes the defining value experienced professionals bring. The question is how we continue to develop it deliberately, rather than assuming it will emerge on its own.

What We Are Testing at PQE Group

We do not yet have a complete solution, but we are exploring several directions with genuine intention. We are strengthening structured mentorship that connects junior and senior professionals around real work rather than scheduled conversations. We are introducing AI-supported workflows anchored in meaningful senior oversight, so that early-career consultants learn to engage critically with outputs rather than accept them passively. And we are creating earlier rotations across quality, regulatory, digital and validation practices to build cross-functional understanding sooner than the traditional path once allowed.

Each of these initiatives contributes something valuable. None of them fully replaces what is being lost, and we remain honest about that as we continue to develop our approach.

The question is not really where the next generation will come from. It is whether we are creating the conditions in which they can develop the judgment our sector depends on.

Read Next

The Reverse Centaur’s Guide to Life After AI by Cory Doctorow

The Reverse Centaur’s Guide to Life After AI by Cory Doctorow

This summer, I have been spending a great deal of time on the road across the United States. Travel always gives me a little more room to read, think, and step outside the pace of daily business. One of the books I picked up along the way was Cory Doctorow’s The...

AI in Life Sciences: The Wrong Question Is Costing You the Right Answer

AI in Life Sciences: The Wrong Question Is Costing You the Right Answer

Will AI replace regulators, quality professionals, and clinical judgment? This question is sparking heated and fearful debate regarding the integration of AI into the Life Sciences industry. But, contrary to popular belief, the issues do not lie in the incorporation...

Designing Decisions in a Changing Pharma Landscape

Designing Decisions in a Changing Pharma Landscape

In pharmaceutical leadership, uncertainty is often described as an emotional climate, yet it profoundly reshapes the conditions under which decisions are made. What is less often acknowledged is how profoundly it reshapes the actual conditions under which decisions...